Interchem launch Equioxx, COX-2 selective NSAID tablet with 24-hour efficacy

Thursday, January 20, 2022

Interchem (Ireland) Ltd. is delighted to add Equioxx to its equine range. Equioxx contains 57mg of firocoxib, the latest generation COX-2 selective equine non-steroidal anti-inflammatory drug (NSAID). Click the title to read more. 
Interchem (Ireland) Ltd. is delighted to add Equioxx to its equine range. Equioxx contains 57mg of firocoxib, the latest generation COX-2 selective equine non-steroidal anti-inflammatory drug (NSAID).
 
Firocoxib has proven clinical efficiency on pain associated with osteoarthritis. Studies showed equal clinical efficacy to flunixin7 and phenylbutazone2. Anti-inflammatory properties of firocoxib have been shown to have strong analgesic response in horses with osteoarthritis demonstrated by improvement in lameness scores2.
 
Long duration of action without therapeutic gap of analgesia. Firocoxib has a long duration of action with sustained therapeutic effect over 24 hours4 which results in eliminating a therapeutic gap that is commonly present with other NSAIDs3,6. Firocoxib is licenced to use up to 14 days.
Unique equine COX-2 selective NSAID. A concentrated action on cyclooxygenase-2 (COX-2) allows Equioxx to act specifically on pain and inflammation while preserving the physiological action of COX-1 and minimising side effects associated with COX-1 inhibition1.
 
Low risk of side effects.  As a selective COX-2 inhibitor1, there is a very low risk of side effects often associated with nonselective COX inhibitors including gastric ulceration, intestinal inflammation, acute renal failure and bone marrow suppression.
 
Convenience.Simple dosing to improve prescription compliance with 1 tablet per 24 hours.

Talk to your local Interchem Territory Manager to find out more out Equioxx and Interchem’s range of equine products.

Further information available at on request. Use Medicines Responsibly.

References:
  1. COOK V.L et al. The use of nonsteroidal anti-inflammatory drugs in critically ill horses. Journal of Veterinary Emergency and Critical Care., 25(1), 2015.
  2. DOUCET M.Y., et al., Comparison of efficacy and safety of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. JAVMA, Vol 232, 1, January 2008.
  3. FOGLE C. et al. Ex vivo COX-1 and COX-2 inhibition in equine blood by phenylbutazone, flunixin meglumine, meloxicam and firocoxib : informing clinical NSAID selection. Equine Veterinary Education 2020.
  4. HOLLAND B., Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horse. J Vet Pharmacol Therapy; 38, 249-256, 2014.
  5. KNYCH H.K., Nonsteroidal anti-inflammatory drug use in horses. Vet Clin Equine 33 (2017).
  6. RAIDAL S.L. et al. Pharmacokinetics and safety of oral administration of Meloxicam to foals. Journal of Veterinary Internal Medicine, 27, 300-307, 2007.
  7. ZIEGLER and al., Multicentre, blinded, randomised clinical trial comparing the use of ­flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction. Equine Veterinary Journal, 51, 329-335, 2018.

T: +353 (0)1 451 8959     F: +353 (0)1 4512540
info@interchem.ie

Interchem (Ireland) Ltd. Unit 29, Cookstown Industrial Estate, Dublin 24, D24 V9FP.

© Copyright 2022 VetHub from Interchem. All rights reserved. Powered by Sana Commerce.